In:
Blood, American Society of Hematology, Vol. 128, No. 22 ( 2016-12-02), p. 4711-4711
Abstract:
Introduction The t(5;11)(q35;p15.4) translocation joining the nucleoporin-98 kD (NUP98) and nuclear receptor binding SET domain protein 1 (NSD1) genes is a recurrent chromosomal aberration in pediatric acute myeloid leukemia (AML). The NUP98-NSD1 frequently co-occurs with FLT3-ITD and with high-rates of induction failure. Analyzing primary samples and cell models by high-throughput drug testing, we aimed to identify alternative therapeutic approaches and better understand the impact of the NUP98-NSD1 and FLT3-ITDalterations on drug response. Methods Bone marrow mononuclear cells (BM MNCs) were prepared from 4 samples collected from two NUP98-NSD1, FLT3-ITD AML patients and 10 healthy donors. Experimental cell models included lineage-marker-depleted mouse bone marrow (BM) cells transduced with chimeric NUP98-NSD1 (NN) and FLT3-ITD (F) retroviruses alone and together (NNF),and Ba/F3 and 32D cells transduced with two NUP98-NSD1 transcripts, cloned from patient material. The cells were dispensed on plates containing up to 309 FDA/EMA-approved investigational small molecule inhibitors and chemotherapeutics in five concentrations over a 10,000-fold range. Cell viability was measured after 72h using the CellTiter-Glo® luminescence assay and drug sensitivity scores (DSS) calculated. In patient samples, a select drug sensitivity score (sDSS) was evaluated by subtracting the mean DSS of the healthy samples from the patient DSS, while in cell lines the DSS of mock-transduced parental cell line was substracted from the DSS of the respective experimental model. For evaluating selectively effective drugs, we considered compounds with DSS and sDSS values above 9 and 4, respectively. Results We identified 19 selectively effective drugs in the patient samples. The highest mean sDSS values were seen for pan-BCL-2 inhibitor navitoclax (11,8), the multikinase inhibitor dasatinib (11,0), and the HSP-90 inhibitor tanespimycin (10,3). Amongst the top selective compounds were also the multikinase inhibitor ponatinib and several HDAC-, MEK-, HSP-90, PI3K-, MTOR-inhibitors. Similar to patient samples, mouse BM cells expressing chimeric NUP98-NSD1, and mouse cells (Ba/F3, 32D) expressing a NUP98 exon-12/NSD1 exon-6 fusion had high mean sDSS to BCL-2 inhibitors: navitoclax (13,9), obatoclax (13,4), and venetoclax (9,6). Analyzing the BCL-2 inhibitor sensitive NUP98-NSD1cells, we identified 32 selectively effective drugs. The top 25 drugs included inhibitors of Aurora A, BRAF, VEGFR, MET, IGF1R, WEE-1, and PI3K. Contrary to the NUP98 exon-12/NSD1 exon-6 fusion, the cells (Ba/F3, 32D) expressing NUP98 exon-11/NSD1 exon-6 fusion were unresponsive to BCL-2 inhibitors. From these cells, we found 14 selectively effective drugs, including glucocorticoids, JAK-, PI3K-, MTOR-, and BET-inhibitors. As an indication of functional synergy, the mouse BM cells expressing both NUP98-NSD1 and FLT3-ITD had significantly increased selective sensitivity to non-specific and specific FLT3-inhibitors (N =11) compared to cells expressing FLT3-ITDalone (p = 0.001). The most selectively effective FLT3-inhibitor in the dual positive mouse BM cells was quizartinib (sDSS = 22,8). Based on the initial results, we designed drug combinations for the 72 most effective drugs. Synergy was observed between dasatinib and MEK1/2-, PI3K-, and several receptor tyrosine kinase inhibitors in the NNF expressing mouse BM cells. In vitally frozen primary cells, we observed synergy between dasatinib and BCL-2- (navitoclax), PI3K-, and MTOR-inhibitors (idelalisib, PF-04691502). Conclusions In summary, we identified potential candidate drugs and drug combinations for targeting NUP98-NSD1 and FLT3-ITD expressing cells. The sensitivity of NUP98-NSD1 cells to BCL-2 inhibitors suggests the fusion may induce BCL-2 mediated survival, while the addition of FLT3-ITD confers sensitivity to FLT3 inhibitors. The results also suggest that alternative NUP98-NSD1 transcripts may have different impacts on the drug responses. Finally, our data indicates that FLT3-inhibitors could offer therapeutic advantage to cells with dual NUP98-NSD1 and FLT3-ITD, and support clinical evaluation of FLT3-inhibitors in chemo-resistant t(5;11) positive AML. Disclosures Porkka: Bristol-Myers Squibb: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Heckman:Pfizer: Research Funding; Celgene: Research Funding.
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood.V128.22.4711.4711
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2016
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7
Bookmarklink
